Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
Clinical Journal of the American Society of Nephrology : CJASN|April 13, 2023
Overcoming Barriers to Drug Development in Children with CKDMona Khurana, Gunter F Egger, Lynne Yao, et al.
Therapeutic Innovation & Regulatory Science|June 18, 2026
Expertise of European Clinical Trial Units in Conducting and Managing Cross-Border Pediatric Clinical Trials for Rare DiseasesBegonya Nafria, Segolene Gaillard, Martine Dehlinger-Kremer, et al.
Frontiers in Medicine|July 25, 2025
New medicines for childhood-onset systemic lupus erythematosus: an EU perspective on paediatric drug developmentRoberto De Lisa, Fernando de Andres-Trelles, Ralph Bax, et al.
International Journal of Toxicology|October 31, 2019
Evaluation of Juvenile Animal Studies for Pediatric CNS-Targeted Compounds: A Regulatory PerspectiveJan Willem van der Laan, Karen van Malderen, Nico de Jager, et al.
Pharmaceutical Medicine|June 22, 2026
Language as an Eligibility Criterion in Pediatric Study Protocols Conducted in Europe (2007-2024) Reported in the ClinicalTrials.gov DatabaseBegonya Nafria, Alexander Perera, Segolene Gaillard, et al.
Plos One|February 21, 2012
Mitochondrial haplogroups and control region polymorphisms in age-related macular degeneration: a case-control studyEdith E Mueller, Elena Schaier, Susanne M Brunner, et al.
Swiss Surgery = Schweizer Chirurgie = Chirurgie Suisse = Chirurgia Svizzera|June 16, 2001
[Multidisciplinary management of hereditary colorectal cancer]C Soravia, C Delozier-Blanchet, J L Blouin, et al.
ESMO Open|November 18, 2022
Clinical and prognostic implications of CD47 and PD-L1 expression in surgically resected small-cell lung cancerC Lang, A Lantos, Z Megyesfalvi, et al.
European Journal of Internal Medicine|August 12, 2024
Treatment of systemic lupus erythematosus: Analysis of treatment patterns in adult and paediatric patients across four European countriesMike Du, Francesco Dernie, Martí Català, et al.
Frontiers in Medicine|February 26, 2025
Requirements and special considerations for drug trials with children across six jurisdictions: 2. Ethics review in the regulatory approval processBreanne Stewart, Pirkko Lepola, Gunter F Egger, et al.
Pageof 6